Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5852668 | 0.80 | KDM4E (0.61) | KDM4EMAPTHPGDHTTHSD17B10 | |
| SCHEMBL8629907 | 0.79 | KDM4E (0.37) | KDM4EMAPTHPGDHTTHSD17B10 | |
| SCHEMBL45690 | 0.78 | MAPT (0.42) | KDM4EMAPTHTTALDH1A1RAB9A | |
| SCHEMBL1472954 | 0.78 | DAO (0.63) | KDM4EMAPTHPGDALDH1A1PKM | |
| SCHEMBL261464 | 0.77 | CSNK2A2 (0.45) | KDM4EMAPTHPGDHSD17B10ALDH1A1 | |
| SCHEMBL1630492 | 0.76 | KDR (0.42) | KDM4EMAPTHTTALDH1A1POLB | |
| SCHEMBL12009470 | 0.75 | USP2 (0.47) | KDM4EMAPTHPGDHTTHSD17B10 | |
| SCHEMBL15988677 | 0.74 | GSK3B (0.48) | KDM4EMAPTALDH1A1POLBRAB9A | |
| SCHEMBL23617317 | 0.74 | GSK3B (0.44) | KDM4EMAPTHPGDHTTHSD17B10 | |
| SCHEMBL7257884 | 0.74 | KDM4E (0.51) | KDM4EMAPTHPGDHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552757-B2 | NRF2-activating compound | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2026-02-17 | — | — | US | disclosed |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4273145-A1 | NRF2-ACTIVATING COMPOUND | Senju Pharmaceutical Co., Ltd. (JP) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273145-A1 | NRF2-ACTIVATING COMPOUND | Senju Pharmaceutical Co., Ltd. (JP) | 2023-11-08 | — | — | EP | disclosed |
| CN-116669744-A | Nrf2 activating compounds | 千寿制药株式会社 | 2023-08-29 | — | — | CN | disclosed |
| US-20230024995-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230024995-A1 | NRF2-ACTIVATING COMPOUND | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| WO-2022145459-A1 | NRF2-ACTIVATING COMPOUND | 千寿製薬株式会社 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022145459-A1 | NRF2-ACTIVATING COMPOUND | 千寿製薬株式会社 | 2022-07-07 | — | — | WO | disclosed |
| EP-3998262-A1 | NRF2-ACTIVATING COMPOUND | Senju Pharmaceutical Co., Ltd. (JP) | 2022-05-18 | — | — | EP | disclosed |
| EP-3998262-A1 | NRF2-ACTIVATING COMPOUND | Senju Pharmaceutical Co., Ltd. (JP) | 2022-05-18 | — | — | EP | disclosed |
| CN-114080389-A | Nrf2 activating compound | 千寿制药株式会社 | 2022-02-22 | — | — | CN | disclosed |
| WO-2021002473-A1 | NRF2-ACTIVATING COMPOUND | 千寿製薬株式会社 | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024995-A1 | NRF2-ACTIVATING COMPOUND | NFE2L2, KEAP1, NFE2 | KDM4E 2390/4885MAPT 3128/4885HPGD 685/4885 |
| US-12552757-B2 | NRF2-activating compound | NFE2L2, NFE2, KEAP1 | KDM4E 1987/4885MAPT 2863/4885HPGD 750/4885 |
| US-20240132519-A1 | NRF2-ACTIVATING COMPOUND | NFE2L2, KEAP1, NFE2 | KDM4E 3587/4885MAPT 2512/4885HPGD 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.